Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strateg…

Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners, providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einst…

Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting, a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collabor…

About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multipl…

Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital. In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading an…

Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines t…

Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs. BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more th…

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s missio…

Brian Culley is the CEO of Lineage Cell Therapeutics, a clinical-stage biotech company whose mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage currently has several programs undergoing clinical and preclinical investigation for indications in ophthalmology,…

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals, a clinical-stage c…

Adrian is an advisor for several biotech companies in Argentina. Before joining CITES, a venture builder from Argentina, he worked as an advisor for RedCrow VC in San Francisco, and has more than 10 years working in the pharmaceutical industry in companies like Novartis and Merck KGaA. In this episode, we discuss his path from academia to big pharm…

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalat…

Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at indu…

Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of …

Dr. Anupam Chakravarty is a researcher whose research interests have straddled the disciplines of biochemistry and genomics with a keen focus on the biology of cancer. Currently, he is a senior scientist developing liquid biopsy assays and products in the precision oncology space at Guardant Health. Prior to joining Guardant Health, he ran his own …

Dr. Tony Russo Ph.D. is the Chairman, CEO, and founder of Russo Partners, a leading public and investor relations firm. He has been a member of the healthcare and technology PR and IR community for more than three decades. As a founder of Noonan/Russo in 1988, he and his colleagues have helped build signature healthcare brands worldwide. A frequent…

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer an…

Dr. Shelley Ackerman is an Associate Director & Program Team Lead at Bolt Biotherapeutics. Bolt is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Biotherapeutics’ proprietary Boltbody™ Immun…

Dr. James Coates is currently the Principal for Health & Human Performance at Decisive Point, an East coast venture capital firm that invests in and supports startups with deep tech and government use cases. James holds a Ph.D. in Cancer Drug Discovery and MSc in Radiation Biology and Oncology, both from the University of Oxford, and he conducted t…

Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncolo…

Dr. Steve Doberstein has had a long career leading Research groups at a number of biotech companies, like “XOMA”- a monoclonal antibody discovery and development company, “Five Prime Therapeutics”- a protein and antibody discovery and development company, “Xencor”- a leader in protein engineering and “Exelixis”-a genomics-based drug discovery compa…

Dr. Daniel Elgort currently serves as the Chief Data and Analytics Officer for M2GEN, a bioinformatics company focused on the acceleration of oncology research discoveries through superior data and analytics services. The company was formed as a spin-off of the Moffitt Cancer Center in Tampa, Florida, serving as the technological hub for an allianc…

Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies- to improve the quality of life and outcomes for patients fighting cancer. Prior to founding OnQuality, sh…

Laura Jacoby is currently an Application Specialist at Apprentice.io, an innovative tech company that offers cloud-based solutions that impact pharmaceutical production at every stage of development. Their goal is to introduce digitization of records in an industry that until recently has operated mainly in a paper and pen world. Laura has a career…

Alex Harding is a Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics, a Boston-based biotech company developing small molecules that alter RNA processing prior to protein translation. Their REMaster platform “enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon…

The crab season is here! If you are a Baltimore resident, you might have enjoyed dozens of our famous blue crabs, perhaps dozens of dozens every year. If you are new to Baltimore, you must have been encouraged to try them. Blue crabs are indeed tasty, but other than their nice savor, what do we know about them? This week on Sci'more podcast, crab b…

Our episode features two leaders at the global specialty pharmaceutical company Kyowa Kirin. Kyowa Kirin has a particular focus on the discovery and development of novel, first-in-class medicines that have a profound impact on patients in multiple therapeutic areas. Rachel Soloff is an executive director of research with expertise in immunology and…

McKane is a 5th year PhD student in the Department of Population, Family and Reproductive Health at Johns Hopkins Bloomberg School of Public Health She is conducting her PhD project under supervision of Dr. Terri Powell (https://www.researchbypowell.com/) trying to identify how multiple levels of support interact to influence positive sexual health…

Dr. Michael Nedelcovych is a Vice President of Equity Research at Cowen Inc., a diversified financial services firm that operates as a broker dealer and investment manager. Mike works on the large cap pharma equity research team – covering large, multinational pharmaceutical organizations – evaluating the performance of those companies in order to …

Eric Vivier is an SVP, CSO, and co-founder of Innate Pharma, a company developing innovative immunotherapy approaches with the goal of eradicating solid and metastatic tumors in the body. Eric is a Doctor of Veterinary Medicine (DVM) from the Ecole Nationale Vétérinaire de Maisons-Alfort and holds a Ph.D. in Immunology from the Paris University (Pa…

Dr. Michelle Ols is a Director and the Head of Cell Therapy at Obsidian Therapeutics. Obsidian Therapeutics is a private, Cambridge-based biotech company focused on the development of engineered cell and gene therapies for a range of indications. Obsidian has also pioneered their proprietary cytoDRiVE™ technology platform that leverages drug-respon…

Peter is a 5th-year PhD student from the Pathobiology program at Johns Hopkins School of medicine. As part of Dr. Laura D. Wood’s lab, his thesis is focused on to understanding new mechanisms of invasion of pancreatic cancer by using patient derived samples in organoid models. The decision to follow the Academic or Industry path has been always in …

Marisa is a fourth-year PhD candidate at the Johns Hopkins University School of Medicine in the Laboratory of Dr. Drew Pardoll. After her undergrad, she worked as a technician in industry for almost 6 years before deciding to go back to Academia to Pursue a PhD. Her thesis involves studying the role of AMPA receptors in T cells in the context of au…

Dr. Greg Verdine is an eminent serial entrepreneur and investor in the life sciences industry. He has founded a number of companies and currently serves as President, CEO, and CSO of both Fog Pharma and LifeMine Therapeutics. Greg also worked in the venture capital industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, WuXi He…

Beyond the Horizons is a mini podcast series about different career paths and relevant professional development topics to discover what lies beyond. Join Ken Igarza (MS Neuroscience), to learn more about his career journey as a NSF-GRFP Graduate Researcher. Hosted by Ona Ambrozaite, Chemistry Ph.D. candidate at Johns Hopkins University, Co-Chair fo…

Beyond the Horizons is a mini podcast series about different career paths and relevant professional development topics to discover what lies beyond. Join Dr. Samantha Black (PhD Nutrition Sciences), Editor-in-Chief at Science Board, to learn more about careers in writing and publishing. Hosted by Marta Sliwa, Chemistry Ph.D. candidate at Johns Hopk…

Beyond the Horizons is a mini podcast series about different career paths and relevant professional development topics to discover what lies beyond. Join Dr. Smiti Nathan (PhD Anthropology), Senior User Experience Researcher, to learn more about careers in UX Research. Hosted by Dr. Roshni Rao, Director of PHutures at Johns Hopkins University. Brou…

Beyond the Horizons is a mini podcast series about different career paths and relevant professional development topics to discover what lies beyond. Join Dr. Abeer Saha (PhD History), Curator at the National Museum of American History, to learn more about careers in museums. Hosted by Dr. Christine Kelly, Associate Director of PHutures at Johns Hop…

Wei-Chiang Chen, PhD is an Associate Director of Bioprocess Analytics in the Genome Medicine Unit at Sanofi, developing cell and gene therapies for areas of high unmet need. Prior to joining Sanofi, Wei-Chiang held positions at several large and small biotech companies including Biogen, Solid Biosciences, and Flexion Therapeutics. Additionally, he …

Dave is the CEO and Chief Scientific Officer of BioPhy, a healthcare fintech company committed to enhancing outcomes for patients and creating value for investors using their proprietary AI technology. Prior to starting BioPhy with his co-founders at the The Wharton School at the University of Pennsylvania where he received his MBA, Dave was a Seni…

Soufiane Aboulhouda is the co-founder and co-president of Nucleate, a new, student-run, non-profit activator program for the next generation of biotech founders. The mission of Nucleate is to train graduate students (PhDs, MBAs, Post-Docs, JDs, MDs, and Master’s) in company creation through a world-class network of advisors plus access to education…

Joe is a fourth-year PhD candidate at the Johns Hopkins University School of Medicine in the Laboratory of Dr. J.N. and R.F. Siliciano. If you are a Hopkins Biotech Podcast follower, you know Joe as the podcast co-director, producer and host. This time we have the pleasure to have him as a guest and to know more about his exciting career. His PhD t…

C.G. Moore, Ph.D., J.D., is a Partner at McBee Moore Woodward & Vanik IP, LLC., a boutique law firm based in Alexandria, Virginia, that specializes in intellectual property management in biotech, pharma, medical devices, and other life sciences-related industries. In this episode, C.G. describes his career path from experiencing the patenting proce…

Gian is a fourth-year PhD candidate at the Johns Hopkins University School of Medicine in the Solomon H. Snyder Department of Neuroscience. His thesis under the supervision of Dr. Dwight Bergles focuses on studying the dynamics and functional significance of cortical remyelination in diverse mouse models of multiple sclerosis. Gian is a Senior Fell…

Christy Wyskiel is the Senior Advisor to the President of Johns Hopkins University for Innovation & Entrepreneurship and the Executive Director of Johns Hopkins Technology Ventures. JHTV is the division of the university responsible for technology transfer, industry research partnerships, and startup acceleration under the brand ‘FastForward.’ Prio…

Ben Portney, Ph.D. is a Senior Associate at Flagship Pioneering, a life sciences venture capital firm specializing in company creation for transformational technologies. Ben is an entrepreneur-scientist, having previously worked in several ventures during his time as a graduate student including NSF I-Corps, an equity research externship at T. Rowe…

Patricia Phelps, PhD is the Associate Director of Academic Career Services at the Johns Hopkins School of Medicine, where she oversees professional development training for graduate students and postdocs. Pat has had an extensive career in biomedical PhD career training, previously serving as the Associate Director for the Professional Development …

Caroline Loew, Ph.D. is the President and CEO of Glympse Bio, an MIT spin out company trying to change the paradigm of in vivo diagnostic and prognostic monitoring for a wide range of disease indications. Prior to running Glympse Bio, Caroline held a number of high-level positions within some of the top global pharmaceutical companies including Mer…

Sam Semenkow, Ph.D. is a Director of Portfolio Intelligence at Bridge Bio, a unique biotechnology company that develops drugs in several modalities for a number of diverse disease areas. Prior to joining Bridge Bio, Sam was an Associate in the equity research group at Citi, a multinational bank. As an equity research associate, Sam covered a number…

Carina Clingman, PhD is a Principal and Founder of Recruitomics Biotalent Consulting, a biotechnology hiring and recruitment agency based in Cambridge, MA. Carina originally trained as a biochemist, earning her PhD in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School. At Recruitomics, she leverages her expe…